Gastric cancer incidence and mortality trends between 2007-2016 in three European countries

Endoscopy ◽  
2021 ◽  
Author(s):  
Diogo Libânio ◽  
Jessica Rocha Rodrigues ◽  
Maria Jose Bento ◽  
Alanna Ebigbo ◽  
Helmut Messmann ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Early Gastric Cancer ◽  
Early Diagnosis ◽  
The Netherlands ◽  
Cancer Diagnosis ◽  
Cancer Incidence ◽  
European Countries ◽  
Easy Access ◽  
Incidence And Mortality ◽  
Over Time

Background/aims: Increased awareness of gastric cancer risk, easy access to upper endoscopy, high-definition endoscopes with virtual chromoendoscopy may have led to an increase in early gastric cancer diagnosis within the last years in Europe. Early diagnosis of gastric cancer may be associated with improved survival. Currently, no data exist on the impact of early diagnosis in gastric cancer patients’ survival at a population level in Europe. Our aim was to assess incidence, early diagnosis rate and gastric cancer survival both in North-Western and Southern European countries with a low to moderate GC incidence. Methods: Data on 41,138 gastric cancer cases between 2007 and 2016 were retrieved from national cancer registries of Belgium, the Netherlands and the Northern Region in Portugal (RORENO). Age standardized incidence and mortality rates (ASMR) were assessed and expressed by 100,000 persons. Early diagnosis was defined as T1 staged tumors (TNM staging). Net survival estimates for 2007-2011 vs 2012-2016 were determined and compared. Results: Age-standardized incidence and mortality decreased over time in Belgium, Northern Portugal and the Netherlands. Early gastric cancer diagnosis increased over time for all the countries. Net 1- year survival improved significantly between the two time periods in all countries and at 5 years in Belgium and Portugal. Conclusions: This is the first study comparing trends in gastric cancer incidence and mortality in some European countries. We found from 2007-2016 a trend towards a rising proportion of T1 gastric cancers and a decrease in ASMR over time, supporting the efforts in secondary prevention strategies.

UPDATE ON THE DIAGNOSIS AND MANAGEMENT OF EARLY GASTRIC CANCER

2015 ◽  
pp. 5-14
Author(s):  
Van Huy Tran ◽  
Quang Trung Tran
Keyword(s):  
Gastric Cancer ◽  
Early Gastric Cancer ◽  
Early Diagnosis ◽  
Cancer Diagnosis ◽  
Good Prognosis ◽  
Accurate Diagnosis ◽  
White Light Endoscopy ◽  
Key Factor ◽  
Magnified Endoscopy ◽  
Endoscopic Characteristics

The prognosis of gastric cancer depends principally upon an early diagnosis. An early and accurate diagnosis of gastric cancer needs some basic knowledges about the endoscopic characteristics of white light endoscopy, chromoendoscopy, magnified endoscopy, FICE and NBI…A strategy of screening is also a key factor for early diagnosis. The treatment of early gastric cancer by endoscopy techniques have showed more and more advantages. Beside of EMR, the technique of ESD is now applied more widely and lead to a very good prognosis and nearly a curative treatment for the patients with early gastric cancer. Key words: gastric cancer, early gastric cancer, diagnosis, endoscopy

scholarly journals Diagnostic value of macrophage inhibitory cytokine 1 as a novel prognostic biomarkers for early gastric cancer screening

2020 ◽  
Author(s):  
Xin Ge ◽  
Xiaolei Zhang ◽  
Yanling Ma ◽  
Shaohua Chen ◽  
Zhaowu Chen ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Early Gastric Cancer ◽  
Cancer Diagnosis ◽  
Early Stage ◽  
Precancerous Lesions ◽  
Diagnostic Value ◽  
Low Grade ◽  
Serum Samples ◽  
Early Screening ◽  
Roc Curve Analysis

Abstract BACKGROUND Early diagnosis is very important to improve the survival rate of patients with gastric cancer, especially in asymptomatic participants. However, low sensitivity of common biomarkers has caused difficulties in early screening of gastric cancer. In this study, we explored whether MIC-1 can improve the detection rate of early gastric cancer.METHODS We screened 8,257 participants based on risk factors such as age, gender, and family history for physical examination including gastroscopy. Participant blood samples were taken for measure MIC-1, CA-199, CA72-4 and PG1/PG2 levels. The diagnostic performance of MIC-1 was assessed and compared with CA-199, CA72-4 and PG1/PG2, and its role in early gastric cancer diagnosis and the assessment of the risk of precancerous lesions have also been studied.RESULTS Based on endoscopic and histopathological findings, 55 participants had gastric cancer, 566 participants had low-grade neoplasia, 2605 participants had chronic gastritis. MIC-1 levels were significantly elevated in gastric cancer serum samples as compared to controls (p<0.001). The sensitivity of serum MIC-1 for gastric cancer diagnosis was much higher than that of CA-199 (49.1% vs. 20.0%) with similar specificities. Moreover, receiver operating characteristic (ROC) curve analysis also showed that serum MIC-1 had a better performance compared with CA-199, CA72-4 and PG1/PG2 in distinguishing early-stage gastric cancer (AUC: 72.9% vs. 69.5%, 67.5%, 44.0% respectively).CONCLUSIONS Serum MIC-1 is significantly elevated in most patients with early gastric cancer. MIC-1 can serve as a novel diagnostic marker of early gastric cancer and value the risk of gastric cancer.

scholarly journals Gastric cancer incidence and mortality is associated with altitude in the mountainous regions of Pacific Latin America

2012 ◽  
Vol 24 (2) ◽  
pp. 249-256 ◽  
Author(s):  
Javier Torres ◽  
Pelayo Correa ◽  
Catterina Ferreccio ◽  
Gustavo Hernandez-Suarez ◽  
Rolando Herrero ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Latin America ◽  
Cancer Incidence ◽  
Mountainous Regions ◽  
Incidence And Mortality

scholarly journals Multi-disciplinary team for early gastric cancer diagnosis improves the detection rate of early gastric cancer

2017 ◽  
Vol 17 (1) ◽  
Author(s):  
Lianjun Di ◽  
Huichao Wu ◽  
Rong Zhu ◽  
Youfeng Li ◽  
Xinglong Wu ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Early Gastric Cancer ◽  
Cancer Diagnosis ◽  
Detection Rate ◽  
Multi Disciplinary Team

scholarly journals Cohort profile: the Women’s Health Accelerometry Collaboration

BMJ Open ◽  
2021 ◽  
Vol 11 (11) ◽  
pp. e052038
Author(s):  
Kelly R Evenson ◽  
John Bellettiere ◽  
Carmen C Cuthbertson ◽  
Chongzhi Di ◽  
Rimma Dushkes ◽  
...  
Keyword(s):  
Physical Activity ◽  
Cohort Studies ◽  
Women’S Health ◽  
Women's Health ◽  
Sedentary Behaviour ◽  
Cancer Diagnosis ◽  
Cancer Incidence ◽  
Cancer Surveillance ◽  
Cancer Outcomes ◽  
Incidence And Mortality

PurposeThis paper describes the Women’s Health Accelerometry Collaboration, a consortium of two prospective cohort studies of women age 62 years or older, harmonised to explore the association of accelerometer-assessed physical activity and sedentary behaviour with cancer incidence and mortality.ParticipantsA total of 23 443 women (age mean 73.4, SD 6.8) living in the USA and participating in an observational study were included; 17 061 from the Women’s Health Study (WHS) and 6382 from the Women’s Health Initiative Objective Physical Activity and Cardiovascular Health (WHI/OPACH) Study.Findings to dateAccelerometry, cancer outcomes and covariate harmonisation was conducted to align the two cohort studies. Physical activity and sedentary behaviour were measured using similar procedures with an ActiGraph GT3X+ accelerometer, worn at the hip for 1 week, during 2011–2014 for WHS and 2012–2014 for WHI/OPACH. Cancer outcomes were ascertained via ongoing surveillance using physician adjudicated cancer diagnosis. Relevant covariates were measured using questionnaire or physical assessments. Among 23 443 women who wore the accelerometer for at least 10 hours on a single day, 22 868 women wore the accelerometer at least 10 hours/day on ≥4 of 7 days. The analytical sample (n=22 852) averaged 4976 (SD 2669) steps/day and engaged in an average of 80.8 (SD 46.5) min/day of moderate-to-vigorous, 105.5 (SD 33.3) min/day of light high and 182.1 (SD 46.1) min/day of light low physical activity. A mean of 8.7 (SD 1.7) hours/day were spent in sedentary behaviour. Overall, 11.8% of the cohort had a cancer diagnosis (other than non-melanoma skin cancer) at the time of accelerometry measurement. During an average of 5.9 (SD 1.6) years of follow-up, 1378 cancer events among which 414 were fatal have occurred.Future plansUsing the harmonised cohort, we will access ongoing cancer surveillance to quantify the associations of physical activity and sedentary behaviour with cancer incidence and mortality.

scholarly journals Prostate cancer incidence and mortality in the Baltic states, Belarus, the Russian Federation and Ukraine

BMJ Open ◽  
2019 ◽  
Vol 9 (10) ◽  
pp. e031856 ◽  
Author(s):  
Ausvydas Patasius ◽  
Kaire Innos ◽  
Anton Barchuk ◽  
Anton Ryzhov ◽  
Marcis Leja ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Incidence ◽  
European Countries ◽  
Eastern European ◽  
Prostate Cancer Incidence ◽  
Incidence And Mortality ◽  
North Eastern ◽  
Eastern European Countries ◽  
The Baltic ◽  
Observation Period

BackgroundProstate cancer incidence varies internationally largely attributable to differences in prostate-specific antigen (PSA) use. The aim of this study was to provide the most recent detailed international epidemiological comparison of prostate cancer incidence and mortality in six north-eastern European countries (Belarus, Estonia, Latvia, Lithuania, the Russian Federation and Ukraine).MethodsThe number of incident prostate cancer cases was obtained from the countries national cancer registries. Prostate cancer mortality and corresponding population data were extracted from the WHO Mortality Database. Age-specific and age-standardised incidence and mortality rates were calculated (European Standard). The joinpoint regression model was used to provide an average annual percentage change and to detect points in time where significant changes in trends occurred. The observation period was between 13 (Ukraine) and 48 (Estonia) years regarding incidence and around 30 years regarding mortality.ResultsThe comparison of prostate cancer incidence in six European countries showed almost sixfold differences in the age-adjusted rates in most recent years with highest incidence rates in Lithuania and Estonia. Through the observation period, overall a continuous rise was seen in incidence in all countries and a continuous rise in mortality, with a stabilisation in Estonia and a decrease in Lithuania in recent years. Data limitations included a descriptive design using ecological data.ConclusionsA widespread use of PSA testing seems to be responsible for the changes in the epidemiology of the disease in north-eastern European countries. Substantial variation in the incidence of prostate cancer in the Baltic states suggests the possibility that PSA performance and utilisation spread have had a major influence on observed incidence trends, with a lack of effect on prostate cancer mortality.

scholarly journals Incidence, Survival, and Mortality Trends of Cancers Diagnosed in Adolescents and Young Adults (15–39 Years): A Population-Based Study in The Netherlands 1990–2016

Cancers ◽  
2020 ◽  
Vol 12 (11) ◽  
pp. 3421
Author(s):  
Daniël J. van der Meer ◽  
Henrike E. Karim-Kos ◽  
Marianne van der Mark ◽  
Katja K. H. Aben ◽  
Rhodé M. Bijlsma ◽  
...  
Keyword(s):  
The Netherlands ◽  
Cancer Patients ◽  
Cancer Incidence ◽  
Relative Survival ◽  
Mortality Rates ◽  
Adolescent And Young Adult ◽  
Mortality Trends ◽  
Netherlands Cancer Registry ◽  
Incidence And Mortality ◽  
Cancer Types

Adolescent and young adult (AYA) cancer patients, aged 15–39 years at primary cancer diagnosis, form a distinct, understudied, and underserved group in cancer care. This study aimed to assess long-term trends in incidence, survival, and mortality of AYA cancer patients within the Netherlands. Data on all malignant AYA tumours diagnosed between 1990–2016 (n = 95,228) were obtained from the Netherlands Cancer Registry. European age-standardised incidence and mortality rates with average annual percentage change (AAPC) statistics and five-year relative survival rates were calculated. The overall cancer incidence increased from 54.6 to 70.3 per 100,000 person-years (AAPC: +1.37%) between 1990–2016, and increased for both sexes individually and for most cancer types. Five-year relative survival overall improved from 73.7% in 1990–1999 to 86.4% in 2010–2016 and improved for both sexes and most cancer types. Survival remained poor (<60%) for rhabdomyosarcoma, lung, stomach, liver, bladder, and pancreatic carcinomas, among others. Mortality rates among male AYAs overall declined from 10.8 to 6.6 (AAPC: −1.64%) and from 14.4 to 10.1 per 100,000 person-years (AAPC: −1.81%) for female AYAs since 1990. Mortality rates remained unchanged for male AYAs aged 20–24 and 25–29 years. In conclusion, over the past three decades, there has been a considerable increase in cancer incidence among AYAs in the Netherlands. Meanwhile, the survival improved and the mortality overall declined. Survival at five-years now well exceeds above 80%, but did not do so for all cancer types.

Sign in / Sign up

Export Citation Format

Share Document